Major stock indexes closed lower on Friday, after the week saw a flurry of events, including DeepSeek scare and earnings ...

The following first ran on CounterPunch at the height of the COVID pandemic in January of 2022. Are anti-vaccine propagandists really being censored?

Bernstein lowered the firm’s price target on Moderna (MRNA) to $45 from $55 and keeps a Market Perform rating on the shares. The firm cites the ...

In a report released yesterday, Courtney Breen from Bernstein maintained a Hold rating on Moderna (MRNA – Research Report), with a price target ...

Volunteers in north Wales are among 25,000 people taking part in a global trial to find a vaccine against the symptoms of the ...

Jim Cramer, the host of Mad Money, reflected on the uncertainty surrounding the year 2025, focusing on several macroeconomic ...

The US Department of HHS is awarding the pharmaceutical company Moderna $590 million to continue developing a vaccine to protect against bird flu.

We recently published a list of These 10 Stocks Were Wednesday’s Worst Performers. In this article, we are going to take a ...

Delving into the details, we found 51% of traders were bullish, while 25% showed bearish tendencies. Out of all the trades we ...

The number of bird flu cases in Central Massachusetts is relatively low, compared to a swath of the state that runs from ...

Moderna Inc (NASDAQ:MRNA) shares are trading lower Wednesday after Goldman Sachs downgraded the stock. Here's what you need ...

Shares of vaccine maker Moderna fell Wednesday as Goldman Sachs lowered its rating after the biotech’s second cut to product ...